Subscribe to our YouTube Channel Dr. Conant was the first physician to diagnose HIV in San Francisco while running the inpatient dermatology service at the University of California San Francisco. Before anyone recognized the virus or understood that it was about to become a global epidemic, Dr. Conant took the lead in forming the Kaposi’s… [Read More]
Subscribe to our YouTube Channel Jeff Galvin, CEO of American Gene Technologies and Rich Bendis, CEO and President of BioHealth Innovation, Inc. have a fireside chat about the rapid evolution of the BioHealth Capital Region. On the heels of Silicon Valley’s branding as one of the world’s largest tech hubs, the BioHealth Capital Region aims… [Read More]
Award Sponsor: CRB This award recognizes the entrepreneurs and startup companies that have achieved strong commercialization momentum behind their innovative technology. Startups fuel the innovation engine in the region and reflect the future growth of any ecosystem. Nominees were selected from companies that showed the most promise, the most momentum, and the most commitment to bringing… [Read More]
Subscribe to our YouTube Channel “We are at the beginning of the technology curve in pharmaceuticals.” Jeff Galvin, CEO of American Gene Technologies (AGT), explains his ascent into the biotechnology drug development field after working closely with computers in Silicon Valley for a large part of his life. This video is the live recording of… [Read More]
Subscribe to our YouTube Channel Contrary to antiretroviral drugs, gene therapy could be used to give the human body immunity to HIV. Dr. David Hardy, a member of American Gene Technologies (AGT)’s HIV Scientific Advisory Board, tells his story of his lifelong commitment to mitigate the effects of the HIV virus. In the past, he… [Read More]
Subscribe to AGT’s YouTube Channel BioNeex, a Biopharmaceutical R&D exchange platform for compounds licensing and co-development partnerships, created an interview series of innovative CEOs and executives to provide value to its customers and the biotechnology industry. Founder Dr. Smbat Rafayelyan interviewed AGT CEO Jeff Galvin as part of its series.
Subscribe to our YouTube Channel Now on the edge of 2020, we’re closer than ever to finding a legitimate therapy to eradicate HIV. Companies like AGT are doing groundbreaking research and developing innovative ways to combat the virus, but without volunteers to participate in clinical trials, efforts to develop a cure could quickly be slowed…. [Read More]
Subscribe to our YouTube Channel Delegate Jared Solomon invited CEO Jeff Galvin to testify to state legislators in Annapolis, Maryland on February 17, 2020. Galvin served as the linkage between public education and the workforce talent pool needed for a thriving Maryland biotech companies, like American Gene Technologies. Listen to his testimony that was recorded… [Read More]
Subscribe to our YouTube Channel AGT’s Jeff Galvin speaks on panel at the BIO CEO & Investor Conference on Feb 10-11. The panel discussed IPO trends and outlook for 2020. The 2020 BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private… [Read More]
Subscribe to our YouTube Channel The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Dr. Pauza was a featured presenter at the conference (press release). In his presentation, he announced details about… [Read More]
Subscribe to our YouTube Channel On June 4th between 1:45 –2:00 pm, CEO Jeff Galvin spoke to audiences attending BIO2019 about AGT’s scientific discoveries, its team of experts, and its plan to move its pre-clinical therapies into the clinic. BIO (Biotechnology Innovation Organization) is the largest trade organization in the world that represents the biotechnology… [Read More]
Subscribe to our YouTube Channel CEO Jeff Galvin presents at Alliance for Regenerative Medicine (ARM)’s 7th Annual Cell & Gene Therapy Investor Day. The event provides institutional, strategic and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.